Changes in modified Glasgow prognostic score after neoadjuvant chemotherapy is a prognostic factor in clinical stage II/III esophageal cancer

Summary The inflammation‐based modified Glasgow prognostic score (mGPS) has been shown to be a prognostic factor for esophageal cancer, but its changes in relation to neoadjuvant chemotherapy (NAC) have never been discussed. The purpose of this study was to evaluate the potential prognostic role of...

Full description

Saved in:
Bibliographic Details
Published in:Diseases of the esophagus 2016-02, Vol.29 (2), p.146-151
Main Authors: Otowa, Yasunori, Nakamura, Tetsu, Takiguchi, Gosuke, Tomono, Ayako, Yamamoto, Masashi, Kanaji, Shingo, Imanishi, Tatsuya, Suzuki, Satoshi, Tanaka, Kenichi, Itoh, Tomoo, Kakeji, Yoshihiro
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
albumin
Biomarkers, Tumor - blood
C-Reactive Protein - analysis
Carcinoma, Squamous Cell - blood
Carcinoma, Squamous Cell - pathology
Carcinoma, Squamous Cell - therapy
chemotherapy
Chemotherapy, Adjuvant - mortality
C‐reactive protein
esophageal cancer
Esophageal Neoplasms - blood
Esophageal Neoplasms - pathology
Esophageal Neoplasms - therapy
Esophageal Squamous Cell Carcinoma
Esophagectomy - mortality
Female
Humans
Hypoalbuminemia - blood
Male
Middle Aged
Multivariate Analysis
neoadjuvant therapy
Neoadjuvant Therapy - mortality
Neoplasm Staging
Prognosis
Serum Albumin - analysis
Survival Rate
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary The inflammation‐based modified Glasgow prognostic score (mGPS) has been shown to be a prognostic factor for esophageal cancer, but its changes in relation to neoadjuvant chemotherapy (NAC) have never been discussed. The purpose of this study was to evaluate the potential prognostic role of mGPS with regard to NAC. mGPS was evaluated on the basis of admission blood samples taken before chemotherapy and before surgery. Patients with elevated C‐reactive protein (CRP) serum levels (>10 mg/L) and hypoalbuminemia (
ISSN:1120-8694
1442-2050
DOI:10.1111/dote.12316